These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 25453091)

  • 1. (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium.
    Jiménez-Díaz MB; Ebert D; Salinas Y; Pradhan A; Lehane AM; Myrand-Lapierre ME; O'Loughlin KG; Shackleford DM; Justino de Almeida M; Carrillo AK; Clark JA; Dennis AS; Diep J; Deng X; Duffy S; Endsley AN; Fedewa G; Guiguemde WA; Gómez MG; Holbrook G; Horst J; Kim CC; Liu J; Lee MC; Matheny A; Martínez MS; Miller G; Rodríguez-Alejandre A; Sanz L; Sigal M; Spillman NJ; Stein PD; Wang Z; Zhu F; Waterson D; Knapp S; Shelat A; Avery VM; Fidock DA; Gamo FJ; Charman SA; Mirsalis JC; Ma H; Ferrer S; Kirk K; Angulo-Barturen I; Kyle DE; DeRisi JL; Floyd DM; Guy RK
    Proc Natl Acad Sci U S A; 2014 Dec; 111(50):E5455-62. PubMed ID: 25453091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial.
    Gaur AH; McCarthy JS; Panetta JC; Dallas RH; Woodford J; Tang L; Smith AM; Stewart TB; Branum KC; Freeman BB; Patel ND; John E; Chalon S; Ost S; Heine RN; Richardson JL; Christensen R; Flynn PM; Van Gessel Y; Mitasev B; Möhrle JJ; Gusovsky F; Bebrevska L; Guy RK
    Lancet Infect Dis; 2020 Aug; 20(8):964-975. PubMed ID: 32275867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A G358S mutation in the Plasmodium falciparum Na
    Qiu D; Pei JV; Rosling JEO; Thathy V; Li D; Xue Y; Tanner JD; Penington JS; Aw YTV; Aw JYH; Xu G; Tripathi AK; Gnadig NF; Yeo T; Fairhurst KJ; Stokes BH; Murithi JM; Kümpornsin K; Hasemer H; Dennis ASM; Ridgway MC; Schmitt EK; Straimer J; Papenfuss AT; Lee MCS; Corry B; Sinnis P; Fidock DA; van Dooren GG; Kirk K; Lehane AM
    Nat Commun; 2022 Sep; 13(1):5746. PubMed ID: 36180431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cation ATPase (ATP4) Orthologue Replacement in the Malaria Parasite Plasmodium knowlesi Reveals Species-Specific Responses to ATP4-Targeting Drugs.
    Mohring F; van Schalkwyk DA; Henrici RC; Blasco B; Leroy D; Sutherland CJ; Moon RW
    mBio; 2022 Oct; 13(5):e0117822. PubMed ID: 36190127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The malaria parasite cation ATPase PfATP4 and its role in the mechanism of action of a new arsenal of antimalarial drugs.
    Spillman NJ; Kirk K
    Int J Parasitol Drugs Drug Resist; 2015 Dec; 5(3):149-62. PubMed ID: 26401486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining SJ733, an oral ATP4 inhibitor of Plasmodium falciparum, with the pharmacokinetic enhancer cobicistat: An innovative approach in antimalarial drug development.
    Gaur AH; Panetta JC; Smith AM; Dallas RH; Freeman BB; Stewart TB; Tang L; John E; Branum KC; Patel ND; Ost S; Heine RN; Richardson JL; Hammill JT; Bebrevska L; Gusovsky F; Maki N; Yanagi T; Flynn PM; McCarthy JS; Chalon S; Guy RK
    EBioMedicine; 2022 Jun; 80():104065. PubMed ID: 35598441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical characterization and chemical inhibition of PfATP4-associated Na
    Rosling JEO; Ridgway MC; Summers RL; Kirk K; Lehane AM
    J Biol Chem; 2018 Aug; 293(34):13327-13337. PubMed ID: 29986883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Manipulating Eryptosis of Human Red Blood Cells: A Novel Antimalarial Strategy?
    Boulet C; Doerig CD; Carvalho TG
    Front Cell Infect Microbiol; 2018; 8():419. PubMed ID: 30560094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selecting an anti-malarial clinical candidate from two potent dihydroisoquinolones.
    Chen Y; Zhu F; Hammill J; Holbrook G; Yang L; Freeman B; White KL; Shackleford DM; O'Loughlin KG; Charman SA; Mirsalis JC; Guy RK
    Malar J; 2021 Feb; 20(1):107. PubMed ID: 33608015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimalarials Targeting the Malaria Parasite Cation ATPase
    Zagórska A; Jaromin A
    Curr Top Med Chem; 2023; 23(3):214-226. PubMed ID: 36411573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations between Varied Susceptibilities to PfATP4 Inhibitors and Genotypes in Ugandan Plasmodium falciparum Isolates.
    Kreutzfeld O; Rasmussen SA; Ramanathan AA; Tumwebaze PK; Byaruhanga O; Katairo T; Asua V; Okitwi M; Orena S; Legac J; Conrad MD; Nsobya SL; Aydemir O; Bailey J; Duffey M; Bayles BR; Vaidya AB; Cooper RA; Rosenthal PJ
    Antimicrob Agents Chemother; 2021 Sep; 65(10):e0077121. PubMed ID: 34339273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Na(+) regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials.
    Spillman NJ; Allen RJ; McNamara CW; Yeung BK; Winzeler EA; Diagana TT; Kirk K
    Cell Host Microbe; 2013 Feb; 13(2):227-37. PubMed ID: 23414762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similarly efficacious anti-malarial drugs SJ733 and pyronaridine differ in their ability to remove circulating parasites in mice.
    SheelaNair A; Romanczuk AS; Aogo RA; Haldar RN; Lansink LIM; Cromer D; Salinas YG; Guy RK; McCarthy JS; Davenport MP; Haque A; Khoury DS
    Malar J; 2022 Feb; 21(1):49. PubMed ID: 35172826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasmid-free CRISPR/Cas9 genome editing in Plasmodium falciparum confirms mutations conferring resistance to the dihydroisoquinolone clinical candidate SJ733.
    Crawford ED; Quan J; Horst JA; Ebert D; Wu W; DeRisi JL
    PLoS One; 2017; 12(5):e0178163. PubMed ID: 28542423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 4-cyano-3-methylisoquinoline inhibitor of Plasmodium falciparum growth targets the sodium efflux pump PfATP4.
    Gilson PR; Kumarasingha R; Thompson J; Zhang X; Penington JS; Kalhor R; Bullen HE; Lehane AM; Dans MG; de Koning-Ward TF; Holien JK; Soares da Costa TP; Hulett MD; Buskes MJ; Crabb BS; Kirk K; Papenfuss AT; Cowman AF; Abbott BM
    Sci Rep; 2019 Jul; 9(1):10292. PubMed ID: 31311978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diverse Chemical Compounds Target Plasmodium falciparum Plasma Membrane Lipid Homeostasis.
    Bhatnagar S; Nicklas S; Morrisey JM; Goldberg DE; Vaidya AB
    ACS Infect Dis; 2019 Apr; 5(4):550-558. PubMed ID: 30638365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spiroindolone NITD609 is a novel antimalarial drug that targets the P-type ATPase PfATP4.
    Turner H
    Future Med Chem; 2016; 8(2):227-38. PubMed ID: 26824174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced deformability of parasitized red blood cells as a biomarker for anti-malarial drug efficacy.
    Deng X; Duffy SP; Myrand-Lapierre ME; Matthews K; Santoso AT; Du YL; Ryan KS; Ma H
    Malar J; 2015 Oct; 14():428. PubMed ID: 26520795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diverse chemotypes disrupt ion homeostasis in the Malaria parasite.
    Lehane AM; Ridgway MC; Baker E; Kirk K
    Mol Microbiol; 2014 Oct; 94(2):327-39. PubMed ID: 25145582
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Barnes CBG; Dans MG; Jonsdottir TK; Crabb BS; Gilson PR
    Front Cell Infect Microbiol; 2022; 12():1060202. PubMed ID: 36530423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.